Morepen Laboratories Ltd

- There are no current plans for fundraising through debt or equity mentioned. - The company is working on regulatory procedures related to the medical devices business but has not planned any capital event yet. - Fundraising or capital raising for the medical devices segment may happen in the future at an appropriate stage, but no concrete plans are on the card currently. - The company emphasizes internal accruals and aims to expand capacity and backward integration using internal resources. - They are a largely debt-free company with negligible debt and have cleared all old debts. - Any future capital-raising for the devices business will depend on business needs and regulatory approvals.

- The company is actively expanding capacities, especially in medical devices and APIs, due to increasing demand. - Major part of capex is directed toward building large sheds to accommodate injection molding and other machinery for backward integration in medical devices. - High-speed machines with higher capacities have been installed in formulation to improve volume and profitability. - Research and development investments include three labs: Okhla (biosensors), Baddi (in-house medical device production), and Bangalore (electronics). - Existing gross block investments mainly cater to API and formulation, with potential to increase topline by approximately Rs. 150-200 crores in API and 2.5-3 times in formulation over the next 1-2 years without major new CAPEX. - The company plans to start shifting medical devices business into a separate company within the financial year, which may involve new licenses and potential capital events or fundraising. - Investments are funded through internal accruals; the company remains largely debt-free.

- Medical Devices segment is the fastest-growing business at 28% CAGR; overall company CAGR is 16%. - Planned meter sales: 30 lakh meters this year, increasing to 36 lakh and then 40 lakh meters in subsequent years. - Strips per meter sold currently ~150, aiming to increase to 155+ (was 165 during COVID due to high usage). - Addressable market for meters estimated at 5 crores; currently at 1 crore installed meters, targeting growth to 2-3 crores over 3-4 years. - Sales growth target: around 27% CAGR for meters to double in 3 years. - Revenues from Strips expected to grow proportionally with meters. - Capacity expansions underway with high-speed machines to meet increasing demand. - API business revenue grew 14% annually; U.S. market grew 32% recently. - Formulation & OTC businesses aim for breakeven with moderate growth (~10%). - Overall company revenue expected to maintain 20% growth, with EBITDA and margins improving alongside volume growth.

- Company expects continued revenue growth with medical devices growing at a CAGR of 28% and overall company CAGR at 16%. - EBITDA margins in devices business projected to increase to 18%-19% due to higher volumes and strip sales per meter. - EBITDA grew more than 101% YoY to Rs. 173 crores; PAT increased 150% to Rs. 97 crores. - EPS has nearly doubled to Rs. 1.88 on Rs. 2 share with Return on Equity improving from 5% to 11%. - Formulation business targeted to reach break-even by FY25, reducing current losses. - API business EBITDA margins improved to 18% from 16% YoY. - Management aims to maintain healthy growth with margins expanding as volumes increase. - Devices business benefits from a “printer cartridge” model, with growing installed meters leading to higher recurring strip sales and improving margins. - Overall long-term growth driven by capacity expansion, backward integration, and market reach enhancement.

- The transcript does not explicitly mention the current or expected order book or pending orders as specific numeric values. - However, it indicates plans for significant expansion: - Planned sale of 30 lakh meters this year, increasing to 36 lakh and then 40 lakh meters in subsequent years. - The business expects growth in strip sales, targeting an increase from 150 to 155 strips sold per meter. - The device business is anticipated to increase margin gradually over the next five years. - There is mention of an expanding market opportunity, including untapped Middle Eastern and South American markets. - The company is focusing on building manufacturing capacity aiming toward a Rs. 5,000 crore scale. - No explicit order backlog numbers, but the tone suggests a growing and robust demand pipeline.